Tumor Lysis Syndrome

Tumor Lysis Syndrome is a condition that can happen when cancer treatments, like chemotherapy, kill off many cancer cells quickly. This can cause a buildup of certain substances in the blood, like uric acid, potassium, and phosphate. It can lead to problems like kidney issues and high blood pressure. Doctors monitor patients for this during treatment.

Condition

What people with Tumor Lysis Syndrome report

Every report comes from a Lived member, sent anonymously.

Have you tried Allopurinol for Tumor Lysis Syndrome?

NameHow it went

About Tumor Lysis Syndrome

What It Is

Tumor lysis syndrome (TLS) is a serious complication of cancer that happens when large numbers of cancer cells break down quickly, usually soon after treatment begins. As the cells burst, they release their contents into the bloodstream faster than the kidneys can clear them. The result is a sudden shift in blood chemistry: uric acid, potassium and phosphate rise, and calcium falls. Those changes matter because they can harm the kidneys and disturb the heart and nerves. Uric acid and calcium phosphate can form crystals that block the kidneys, high potassium can cause dangerous heart rhythm problems, and low calcium can cause cramps or seizures. TLS most often appears within the first week of treatment. It is largely preventable when people at risk are identified early, which is why cancer teams plan for it before treatment starts.

Causes & Risk Factors

TLS is driven by how much cancer there is and how quickly it responds to treatment. It is most common with fast-growing blood cancers, especially aggressive lymphomas such as Burkitt lymphoma and diffuse large B-cell lymphoma, acute lymphoblastic leukemia and acute myeloid leukemia. A very high white blood cell count, a large tumor mass, widespread disease and a high level of lactate dehydrogenase (LDH, an enzyme that rises when cells are turning over rapidly) all point to higher risk. It is less common with slower cancers and most solid tumors, but it can still occur when a treatment works very effectively. Some newer targeted medicines carry a well-known risk; venetoclax (Venclexta), used for chronic lymphocytic leukemia and acute myeloid leukemia, is started at a low dose and increased gradually for this reason. Existing kidney problems and dehydration make TLS more likely and more severe. Rarely, TLS begins on its own before any treatment, in a very fast-growing cancer.

How It's Diagnosed

TLS is diagnosed with blood tests, not by symptoms alone. People at risk usually have blood drawn before treatment and then repeatedly during the first days, sometimes every 6 to 8 hours in the hospital. The tests measure uric acid, potassium, phosphate, calcium and creatinine (a marker of kidney function). Dangerous changes can develop without any symptoms, so these scheduled tests are the main way problems are caught. Clinicians generally describe two levels. Laboratory TLS means two or more of these values have become abnormal around the start of treatment. Clinical TLS means those lab changes are accompanied by a complication: worsening kidney function, an irregular heart rhythm or a seizure. The distinction matters because clinical TLS needs urgent, closer care. The team also checks urine output and looks for other explanations, such as dehydration or infection, that can affect the same tests.

Treatment Options

The best treatment is prevention, scaled to each person's risk. For many people, this means extra fluids through an IV before and during treatment so the kidneys keep producing plenty of urine, along with medicine to lower uric acid and close monitoring of blood chemistry and urine output. Extra potassium and phosphate are avoided during the risk period. Two medicines are commonly used for uric acid. Allopurinol, the same medicine used for gout, reduces how much uric acid the body makes and is a usual choice for people at moderate risk. Rasburicase (Elitek), given by IV, breaks down uric acid that is already in the blood and works faster, so it is used for people at high risk or with TLS already developing. Rasburicase cannot be given to people with glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited enzyme condition, because it can destroy red blood cells, so people with a higher chance of this condition are tested first. If TLS develops despite prevention, care usually moves to closer monitoring, sometimes in an intensive care unit with continuous heart monitoring. Treatment targets each abnormality, for example medicines that move potassium out of the blood and protect the heart. Dialysis is used when kidney function keeps worsening, fluid builds up or chemistry changes cannot be controlled with medicine.

What to Expect

For most people, TLS is something the care team watches for rather than something they experience. The practical effect is a period of extra fluids, frequent blood draws and sometimes a hospital stay at the start of treatment or when a dose is increased. Some medicines that carry a high risk are started in the hospital so blood can be checked within hours. People taking oral medicines at home may be asked to drink a set amount of water each day and to keep every scheduled lab appointment. Prevention works well but does not remove the risk entirely; a small share of people still develop some degree of TLS. When it is caught early, the chemistry changes can usually be corrected with treatment. Kidney injury that needs dialysis, heart rhythm problems and serious infection are the complications most linked to poorer outcomes, which is why the team acts on early lab changes. The risk is highest in the first days of treatment and usually falls as the cancer mass shrinks.

When to Seek Help

Before a new cancer treatment, ask your team whether you are at risk of TLS and what your prevention and monitoring plan is, especially if you have kidney problems. During the risk period, contact your care team right away if you notice nausea or vomiting, confusion, unusual tiredness, muscle cramps or tingling, fever or chills, shortness of breath, or dark or cloudy urine or much less urine than usual. Call 911 for a seizure, fainting, or an irregular or racing heartbeat with feeling faint, since these can signal dangerous potassium or calcium levels.

Questions to Ask Your Doctor

  1. 1.How high is my risk of tumor lysis syndrome with this treatment, and what makes it higher or lower?
  2. 2.What will prevention involve for me, and will any of it need to happen in the hospital?
  3. 3.How often will my blood be tested, and who will tell me if the results change?
  4. 4.Should I be tested for G6PD deficiency before treatment?
  5. 5.How much should I drink at home, and what should I avoid while I'm at risk?

Last reviewed • Oct 2026

Educational content, not medical advice.